
FOXO4-DRI retro-inverso peptide, 15 mg lyophilized at 98.5% HPLC purity for senescence research.
FOXO4-DRI is a D-retro-inverso peptide widely cited in senescent-cell literature and supplied here as a characterised reference material. Every PureLabs lot of FOXO4-DRI is produced under GMP-aligned synthesis controls, assayed by an independent partner laboratory using reverse-phase HPLC with mass-spectrometric confirmation, and released only above the stated purity threshold of 98.5%. The certificate of analysis is lot-specific, carries the chromatogram and MS trace for the exact vial you receive, and stays archived under reference SEQ-1102 for as long as the batch exists.
Common laboratory questions about sourcing, purity, storage and shipping of FOXO4-DRI.
Current stock assays at 98.5% by reverse-phase HPLC, confirmed by mass spectrometry at an independent laboratory. Any lot testing below the threshold is rejected rather than sold.
Yes. A lot-specific certificate of analysis including the HPLC chromatogram and MS trace accompanies every FOXO4-DRI order and remains retrievable under batch reference SEQ-1102.
Sealed lyophilized FOXO4-DRI is stable at −20 °C for at least 24 months; once reconstituted, hold at 2–8 °C and use within about three weeks.
Orders confirmed before 15:00 UTC dispatch the same working day in insulated, tracked cold-chain packaging, subject to the import rules of the destination country.
No. PureLabs supplies this compound strictly as reference material for in-vitro and laboratory research. It is not a medicine and is not for human or veterinary consumption.